Ingrid Zhang
Known title: Chief Executive OfficerCIK: 0001964342
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Morgan Stanley raises Mettler-Toledo price target to $1,575. Morgan Stanley maintained an Equal-Weight rating on Mettler-Toledo while raising its price target to $1,575. This action aligns with the current average analyst target of $1,529.46, which sits below the stock's 52-week high of $1,619.58. The company is also scheduled to host an investor meeting in the near term.
Transaction History
| LEGN | ▲ Buy | Grant | 1,131,860 | $0 | 9/15/2026 | View on chart |
| MTD | ▲ Buy | Grant | 63 | $0 | 11/11/2025 | View on chart |
| MTD | ▲ Buy | Grant | 71 | $0 | 11/12/2024 | View on chart |
| MTD | ▲ Buy | Grant | 49 | $0 | 11/9/2023 | View on chart |
| MTD | ▲ Buy | Grant | 24 | $0 | 2/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Legend Biotech Faces Revised Valuation After CARVYKTI Data
Legend Biotech’s valuation is under review after the release of five‑year CARVYKTI data. JP Morgan and RBC Capital both lowered their price targets to $33 and $56 respectively, signaling a more cautious outlook. The stock is near its 52‑week low and currently tests support at $18.75, adding pressure to the revised targets.
Legend Biotech Faces Revised Valuation After CARVYKTI Data. Legend Biotech’s valuation is under review after the release of five‑year CARVYKTI data. JP Morgan and RBC Capital both lowered their price targets to $33 and $56 respectively, signaling a more cautious outlook. The stock is near its 52‑week low and currently tests support at $18.75, adding pressure to the revised targets.